Summary
Citalopram, a selective 5-HT uptake inhibitor with antidepressant properties, was assessed in three studies in 12 healthy subjects using a battery of EEG, psychological, subjective and symptomatic measures.
Study A involved the administration of citalopram, 20 mg and 40 mg, amitriptyline 50 mg and placebo in single dose using a balanced cross-over design. The test battery was applied before, and 1 and 3 h after each drug. Citalopram decreased slow-wave EEG activity whereas amitriptyline increased power in most EEG wavebands. Citalopram increased tapping rate and symbol copying whereas amitriptyline impaired these and other psychomotor tasks. Subjectively, amitriptyline was much more sedative than citalopram and produced more complaints of dry mouth.
Study B comprised the administration of citalopram in the usual clinical dose of 40 mg, amitriptyline in the low clinical dose of 75 mg and placebo, each given for 9 nights using a balanced cross-over design. The test battery was applied on the first morning (pre-drug) and on the morning after the last nightly dose. None of the physiological tests showed any drug effects. Subjectively, citalopram was associated with feelings of shaking, nausea, loss of appetite and physical tiredness; amitriptyline produced feelings of shaking, nausea, loss of appetite, dryness of mouth, irritability, dizziness and indigestion; in general, amitriptyline effects were more marked than those of citalopram. Plasma samples were taken on the last day and plasma concentrations of both drugs and their metabolites were found to be in the expected range for the regimens used.
In the third study (C), 12 healthy subjects took similar courses of citalopram, amitriptyline and placebo. On the morning of the 8th day, a test dose of ethanol was given. The battery of tests was given predrug, on Days 4/5 and on Day 8, before and 1 and 3 h after the ethanol. Amitriptyline increased the 7.5–13.5 Hz waveband. Amitriptyline impaired critical flicker fusion frequency, tapping, DSST and reaction time; citalopram affected DSST and immediate memory recall. The subjective and symptomatic effects of the drugs were similar to those in Study B. Plasma concentrations of citalopram, amitriptyline and their desmethylated metabolites were in the expected range for the regimens used.
Ethanol had the expected effects, impairing performance and producing sedation. No evidence for potentiation of ethanol and drug effects were found, most interactions being additive, or even with some symptoms subtractive.
It is concluded that in clinical use citalopram should have little or no effect on cognitive and psychomotor performance, produce minimal sedation but some nausea, loss of appetite and insomnia. Interactions with ethanol should be unremarkable.
Similar content being viewed by others
References
Bennett JF (1967) Is there a superior antidepressant? In: Garattini S, Dukes MNG (eds) Antidepressant drugs. Internat Congr Series No. 122. Excerpta Medica, Amsterdam, pp 375–393
Bjerkenstedt L, Flyckt L, Fredricson Overø K, Lingjaerde O (1985) Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. Eur J Clin Pharmacol 28: 553–557
Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211–218
Burrows GD, Norman TR (1981) Tricyclic antidepressants. Plasma levels and clinical response. In: Burrows GD, Norman TR (eds) Psychotropic drugs. Plasma concentration and clinical response. Dekker, New York, pp 169–204
Christensen AV et al. (1977) Pharmacology of a new phthalane (Lu 10–181) with specific 5-HT uptake inhibiting properties. Eur J Pharmacol 41: 153–162
de Wilde J, Mertens C, Fredricson Overø K, Hopfner Petersen HE (1985) Citalopram versus mianserin. A controlled, double-blind trial in depressed patients. Acta Psychiatr Scand 72: 89–96
Fredricson Overø K (1981) Fluorescence assay of citalopram and its metabolites in plasma by scanning densitometry of thin-layer chromatograms. J Chromatogr 224: 526–531
Fredricson Overø K (1982) Kinetics of citalopram in man; plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 6: 311–318
Golombok S, Lader M (1984) The psychopharmacological effects of premazepam, diazepam and placebo in healthy human subjects. Br J Clin Pharmacol 18: 127–133
Gottlieb P, Wandall T, Fredriscon Overø K (1980) Initial, clinical trial of a new, specific 5-HT reuptake inhibitor, citalopram (Lu 10–171). Acta Psychiatr Scand 62: 236–244
Hyttel J (1977a) Effects of a selective 5-HT uptake inhibitor — Lu 10–171 — on rat brain 5-HT turnover. Acta Pharmacol Toxicol 40: 439–446
Hyttel J (1977b) Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10–171. Psychopharmacology 51: 225–233
Hyttel J (1978) Effect of a specific 5-HT uptake inhibitor, Citalopram (Lu 10–171), on 5-HT uptake in rat brain synaptosomes in vitro. Psychopharmacology 60: 13–18
Hyttel J (1982) Citalopram — Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 6: 277–295
Jorgensen A (1975) A gas chromatographic method for the determination of amitriptyline and nortriptyline in human serum. Acta Pharmacol Toxicol 36: 79–90
Kragh-Sorensen P, Fredricson Overø K, Lindegaard Petersen O, Jensen K, Parnas W (1981) The kinetics of citalopram: Single and multiple dose studies in man. Acta Pharmacol Toxicol 48: 53–60
Lemberger L, Fuller RW, Zerbe RL (1985) Use of specific serotonin uptake inhibitors as antidepressants. Clin Neuropharmacol 4: 299–317
Lemberger L, Rowe H, Bergstrom RF et al. (1985) Effect of fluoxetine on psychomotor performance, physiologic response, and kinetics of ethanol. Clin Pharmacol Ther 37: 658–664
Lindegaard Pedersen O, Kragh-Sorensen P, Bjerre M et al. (1982) Citalopram, a selective serotonin reuptake inhibitor: Clinical antidepressive and long-term effect — a Phase II study. Psychopharmacology 77: 199–204
Linnoila M, Dubyoski KV, Rawlings PR, Rudorfer MV, Eckardt MJ (1985) Effects of chronic zimelidine and ethanol on psychomotor performance. J Clin psychopharmacol 5: 148–153
Lindegaard Pedersen O (1982) Citalopram, a selective serotonin reuptake inhibitor: Clinical antidepressive and long-term effect — a Phase II study. Psychopharmacology 77: 199–204
Morris JB, Beck AT (1974) The efficacy of antidepressant drugs. A review of research (1958–1972). Arch Gen Psychiatry 30: 667–674
Ofsti E (1982) Citalopram — a specific 5-HT-reuptake inhibitor — as an antidepressant drug: A Phase II multicentre trial. Prog Neuropsychopharmacol Biol Psychiatry 6: 327–335
Seppala T, Linnoila M (1983) Effects of zimeldine and other antidepressants on skilled performance: a comprehensive review. Acta Psychiatr Scand 308 [Suppl 68]: 135–140
Warrington SJ, Ankier SI, Turner P (1984) An evaluation of possible interactions between ethanol and trazodone or amitriptyline. Br J Clin Pharmacol 18: 549–557
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lader, M., Melhuish, A., Frcka, G. et al. The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol 31, 183–190 (1986). https://doi.org/10.1007/BF00606656
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00606656